MX390894B - Polipéptido de fusión anti-cáncer. - Google Patents
Polipéptido de fusión anti-cáncer.Info
- Publication number
- MX390894B MX390894B MX2017014716A MX2017014716A MX390894B MX 390894 B MX390894 B MX 390894B MX 2017014716 A MX2017014716 A MX 2017014716A MX 2017014716 A MX2017014716 A MX 2017014716A MX 390894 B MX390894 B MX 390894B
- Authority
- MX
- Mexico
- Prior art keywords
- fusion polypeptide
- gpc3
- fusion
- compositions
- nucleic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167927 | 2015-05-18 | ||
| EP16150508 | 2016-01-08 | ||
| PCT/EP2016/061071 WO2016184882A1 (en) | 2015-05-18 | 2016-05-18 | Anti-cancer fusion polypeptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017014716A MX2017014716A (es) | 2018-06-28 |
| MX390894B true MX390894B (es) | 2025-03-21 |
Family
ID=56134305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014716A MX390894B (es) | 2015-05-18 | 2016-05-18 | Polipéptido de fusión anti-cáncer. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10913778B2 (enExample) |
| EP (2) | EP4219535A1 (enExample) |
| JP (1) | JP6947642B2 (enExample) |
| KR (1) | KR102685748B1 (enExample) |
| CN (1) | CN108112253B (enExample) |
| AU (1) | AU2016262845B2 (enExample) |
| CA (1) | CA2980838A1 (enExample) |
| DK (1) | DK3298030T5 (enExample) |
| ES (1) | ES2938525T3 (enExample) |
| FI (1) | FI3298030T3 (enExample) |
| HR (1) | HRP20230145T1 (enExample) |
| HU (1) | HUE061108T2 (enExample) |
| LT (1) | LT3298030T (enExample) |
| MX (1) | MX390894B (enExample) |
| PL (1) | PL3298030T3 (enExample) |
| RS (1) | RS64002B1 (enExample) |
| RU (2) | RU2754466C2 (enExample) |
| SG (1) | SG11201707426SA (enExample) |
| SI (1) | SI3298030T1 (enExample) |
| SM (1) | SMT202300026T1 (enExample) |
| WO (1) | WO2016184882A1 (enExample) |
| ZA (1) | ZA201706061B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10927154B2 (en) * | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| AU2016258952C1 (en) * | 2015-05-04 | 2020-12-24 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| CA2988831A1 (en) | 2015-07-15 | 2017-01-19 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for lag-3 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| KR20190099527A (ko) * | 2017-01-03 | 2019-08-27 | 에프. 호프만-라 로슈 아게 | 항-4-1bb 클론 20h4.9를 포함하는 이중특이성 항원 결합 분자 |
| JP7267921B2 (ja) | 2017-01-06 | 2023-05-02 | クレシェンド・バイオロジックス・リミテッド | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 |
| WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
| RU2019122482A (ru) * | 2017-01-18 | 2021-02-19 | Пирис Фармасьютикалс Гмбх | Мутеины липокалина с аффинностью связывания в отношении lag-3 |
| CA3082297A1 (en) * | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| WO2019185598A1 (en) | 2018-03-26 | 2019-10-03 | 4Sc Ag | Combination comprising hdac inhibitor and cd137 agonist for cancer therapy |
| LT3830120T (lt) * | 2018-07-31 | 2023-07-10 | Pieris Pharmaceuticals Gmbh | Naujas sulietas baltymas specifinis cd137 ir pd-l1 atžvilgiu |
| IL284687B2 (en) * | 2019-02-26 | 2025-11-01 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
| US20220168387A1 (en) * | 2019-03-29 | 2022-06-02 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| WO2020208049A1 (en) * | 2019-04-12 | 2020-10-15 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising lipocalin muteins |
| AU2020260931B2 (en) * | 2019-04-23 | 2023-08-24 | Lg Chem, Ltd. | Fusion polypeptide comprising Fc region of immunoglobulin and GDF15 |
| AU2020301161B2 (en) | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| TWI860386B (zh) * | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| WO2024064713A1 (en) * | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2032831T5 (es) | 1986-08-19 | 2001-02-16 | Genentech Inc | Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| NZ285664A (en) | 1994-05-18 | 1998-07-28 | Inhale Therapeutic Syst | Dry powder interferon composition adapted for pulmonary delivery |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CN1170543C (zh) | 1998-06-08 | 2004-10-13 | 弗·哈夫曼-拉罗切有限公司 | PEG-IFN-α和三唑核苷在治疗慢性丙型肝炎中的用途 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| WO2002024866A2 (en) | 2000-09-21 | 2002-03-28 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
| EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| SG173332A1 (en) | 2006-08-01 | 2011-08-29 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| CN101516907B (zh) | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| DK2178921T3 (en) | 2007-07-17 | 2016-04-04 | Squibb & Sons Llc | Monoclonal antibodies to glypican 3 |
| EP2235053A1 (en) | 2007-10-19 | 2010-10-06 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| EP3381933B1 (en) | 2008-06-24 | 2020-06-03 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| EP2510357B1 (en) | 2009-12-07 | 2016-03-30 | Pieris AG | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| CN103154023B (zh) | 2010-08-16 | 2017-04-05 | 皮里斯制药有限公司 | 铁调素的结合蛋白 |
| SG10201912092VA (en) * | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| US9260492B2 (en) | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| US9522940B2 (en) * | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| CA2913127A1 (en) * | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Methods for screening |
| US20140242077A1 (en) * | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| CN107460201A (zh) * | 2013-05-08 | 2017-12-12 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| US10927154B2 (en) * | 2014-01-13 | 2021-02-23 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| KR102568808B1 (ko) * | 2014-04-07 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 면역활성화 항원 결합 분자 |
| RU2720688C2 (ru) | 2015-01-28 | 2020-05-12 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Новые белки, специфические в отношении ангиогенеза |
| AU2016221816B2 (en) | 2015-02-18 | 2020-07-02 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for pyoverdine and pyochelin |
| AU2016258952C1 (en) * | 2015-05-04 | 2020-12-24 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| AU2016258977C1 (en) | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| US10273275B2 (en) * | 2015-05-18 | 2019-04-30 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-05-18 RU RU2017135539A patent/RU2754466C2/ru active
- 2016-05-18 FI FIEP16729794.4T patent/FI3298030T3/fi active
- 2016-05-18 CA CA2980838A patent/CA2980838A1/en active Pending
- 2016-05-18 US US15/575,309 patent/US10913778B2/en active Active
- 2016-05-18 MX MX2017014716A patent/MX390894B/es unknown
- 2016-05-18 SM SM20230026T patent/SMT202300026T1/it unknown
- 2016-05-18 RU RU2021119777A patent/RU2021119777A/ru unknown
- 2016-05-18 HR HRP20230145TT patent/HRP20230145T1/hr unknown
- 2016-05-18 HU HUE16729794A patent/HUE061108T2/hu unknown
- 2016-05-18 SI SI201631659T patent/SI3298030T1/sl unknown
- 2016-05-18 PL PL16729794.4T patent/PL3298030T3/pl unknown
- 2016-05-18 JP JP2017560331A patent/JP6947642B2/ja active Active
- 2016-05-18 AU AU2016262845A patent/AU2016262845B2/en active Active
- 2016-05-18 SG SG11201707426SA patent/SG11201707426SA/en unknown
- 2016-05-18 LT LTEPPCT/EP2016/061071T patent/LT3298030T/lt unknown
- 2016-05-18 RS RS20230084A patent/RS64002B1/sr unknown
- 2016-05-18 CN CN201680028941.3A patent/CN108112253B/zh active Active
- 2016-05-18 DK DK16729794.4T patent/DK3298030T5/da active
- 2016-05-18 WO PCT/EP2016/061071 patent/WO2016184882A1/en not_active Ceased
- 2016-05-18 EP EP22216061.6A patent/EP4219535A1/en active Pending
- 2016-05-18 ES ES16729794T patent/ES2938525T3/es active Active
- 2016-05-18 EP EP16729794.4A patent/EP3298030B1/en active Active
- 2016-05-18 KR KR1020177035641A patent/KR102685748B1/ko active Active
-
2017
- 2017-09-06 ZA ZA2017/06061A patent/ZA201706061B/en unknown
-
2021
- 2021-02-05 US US17/169,209 patent/US11919931B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
| MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
| MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
| SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
| ZA202104287B (en) | Novel fusion proteins specific for cd137 and gpc3 | |
| PH12017501583B1 (en) | Novel proteins specific for cd137 | |
| JOP20220225B1 (ar) | ميوتينات إنترليوكين-21 وطرق العلاج | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| BR112019005587A2 (pt) | proteínas de ligação recombinantes e sua utilização | |
| BR112017007093A2 (pt) | composições e métodos de uso para aumento da resposta imune e terapia do câncer | |
| PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
| MX2018000447A (es) | Novedosas proteinas especificas para lag-3. | |
| SA522432139B1 (ar) | بروتينات ربط متعددة الخصوصية لمعالجة السرطان | |
| BR112019004711A2 (pt) | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos | |
| BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
| MX384075B (es) | Nuevas proteínas específicas para la angiogénesis. | |
| BR112016027024A2 (pt) | polipeptídeos de ligação específica e seus usos | |
| MX2018015110A (es) | Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos. | |
| MX2019014365A (es) | Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos. | |
| AR115878A1 (es) | Proteínas de fusión específicas para cd137 y pd-l1 |